|
|
|
|
|
Company News |
|
|
|
WuXi Biology/HD Biosciences Presented at Webinar of "New Technologies for Target Discovery and Validation" |
|
Shanghai, China – March 1st, 2022 |
|
| Novel target discovery and validation are the most crucial steps and prerequisites for successful drug development. In WuXi AppTec webinar on Feb. 16th, HDB’s Dr. Shelley Zhang, Head of Exploratory Biology and Immunology, presented the comprehensive target discovery and validation platforms propelled by various new technologies, and extension to the challenging field of immunology and oncology, as well as utilization in multiple new |
| modalities for drug discovery. |
|
| In the presentation, the following topics are introduced: |
|
• |
|
Comprehensive target discovery and validation platforms propelled by CRISPR and other |
|
new technologies |
|
|
• |
Gene editing in various human and mouse primary immune cells |
|
|
• |
TCR-T and CAR-T cell therapy platforms for all-around services, including surface |
| |
antigen validation, in vitro and in vivo efficacy and functional assessment |
|
|
• |
Advanced new modality development in PROTAC/Target Protein Degradation (TPD), |
|
Antibody-oligo conjugate (AOC) and RNA editing (ASO) |
|
|
Please use the link below to review the video: |
|
 |
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
---------------------- |
|
|
---------------------- |
|
|
|
|
|
|
|
|
|
|
|
|
|
沪公网安备 31011502003320号